MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects of serotonergic hallucinogen mescaline have been approved by the local Swiss ethics committee. The trial is set to start next month at the University Hospital Basel Liechti Lab, in Basel, Switzerland.

Mescaline is an archetypical psychedelic that has a long non-regulated history of spiritual use. According to clinical pharmacology professor Dr. Matthias Liechti, there’s little contemporary scientific information on the therapeutic potential of mescaline. “This study will, we believe, provide the first modern research data on mescaline regarding dosing and mechanism of action in humans,” says Dr. Liechti. The compound is said to be similar to LSD and psilocybin in terms of hallucinogenic effects.

The company believes mescaline will have an effect on enhancing the communication between different parts of the brain “that are otherwise inaccessible to the conscious mind.” The study is focused on serotonin 2A (f-HT2A) receptor, which is currently believed to mediate acute alterations of consciousness that are induced by LSD and psilocybin.

The study will use a double-blind, placebo-controlled, cross-over design with six different dosing conditions. 

MindMed last traded at US$3.44 on the Nasdaq.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

MindMed Closes $34.5 Million Financing, Cash Reserves Said To Be At $85 Million

Mind Medicine (NEO: MMED) has completed its previously announced bought deal private placement, raising gross...

Friday, December 11, 2020, 09:15:15 AM

MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to...

Tuesday, October 26, 2021, 10:35:00 AM

Mind Medicine To Conduct $25.0 Million Bought Deal Financing

Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this...

Friday, October 9, 2020, 09:01:05 AM

MindMed Reveals Favorable Results From Phase 1 Trial Of Drug Candidate For Opioid Withdrawal Treatment

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results...

Thursday, May 19, 2022, 09:29:00 AM

Mind Medicine Announces $10.0 Million Bought Deal At Large Discount To Share Price

Mind Medicine (NEO: MMED) this morning announced a bought deal financing with Eight Capital as...

Tuesday, May 5, 2020, 09:14:31 AM